Supha Pharmachem Share Price
0.27-0.01 (-3.57%)
-78.91% past 1 Year
Financial overview
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
CAGR%
Sales
Profits
Returns
ROE
| 10Y | 5Y | 3Y | TTM |
|---|---|---|---|
| - | - | - | 0% |
| - | - | - | 0% |
| - | -33% | -84% | -78% |
| 5% | 5% | 5% | 5% |
Peer Comparison
Symbol
ADANIENT-A
PREMIERENE-A
AEGISLOG-A
CPPLUS-A
REDINGTON-A
HONASA-A
LLOYDSENT-A
CELLO-A
JSLL-A
BLACKROSE-T
SUPHA-Z
| Price | M.Cap (₹) | PE Ratio | EPS (₹) | EV/EBITDA | Annual PAT |
|---|---|---|---|---|---|
| 2,936 | ₹390684 Cr | 52.48 | -8.91 | 105.06 | ₹9339 Cr |
| 998 | ₹45486 Cr | 27.32 | 10.2 | 45.28 | ₹1510 Cr |
| 1,267 | ₹45144 Cr | 36.08 | 13.8 | 41.65 | ₹898 Cr |
| 3,722.05 | ₹44346 Cr | 92.91 | 12.07 | 45.29 | ₹368 Cr |
| 371.6 | ₹29113 Cr | 17.12 | 6.22 | 24.36 | ₹1490 Cr |
| 476.5 | ₹15566 Cr | 62.55 | 2.77 | 8.99 | ₹200 Cr |
| 74 | ₹10984 Cr | 97.81 | 0.38 | 0.91 | ₹283 Cr |
| 342.6 | ₹7747 Cr | 24.77 | 3.32 | 17.46 | ₹332 Cr |
| 518.95 | ₹6238 Cr | 26.37 | 5.29 | 23.32 | ₹222 Cr |
| 114.2 | ₹572 Cr | 19.99 | 2.04 | 6.4 | ₹22 Cr |
| 0.27 | ₹25 Cr | 11.6 | 0.1 | 0.02 | ₹2 Cr |
Profit & Loss
Consolidated
Standalone
Quarterly
Yearly
₹
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
| Sep 2025 | Jun 2025 | Mar 2025 |
|---|---|---|
| ₹111 Cr | ₹113 Cr | ₹264 Cr |
| ₹3 Cr | ₹3 Cr | ₹66 L |
| ₹114 Cr | ₹117 Cr | ₹265 Cr |
| ₹104 Cr | ₹111 Cr | ₹265 Cr |
| ₹11 Cr | ₹5 Cr | ₹20 L |
| ₹19 L | -₹37 L | ₹2 Cr |
| ₹10 Cr | ₹6 Cr | -₹1 Cr |
| ₹9 Cr | ₹5 Cr | -₹2 Cr |
Balance Sheet
Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Deferred Tax Assets / Liabilities
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Net Block
Total Non-Current Assets
Current Assets Loans & Advances
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
| Mar 2025 |
|---|
| — |
| ₹40 Cr |
| ₹4 Cr |
| ₹4 Cr |
| ₹44 Cr |
| -₹4 L |
| -₹4 L |
| — |
| ₹501 Cr |
| ₹32 Cr |
| ₹1141 Cr |
| ₹2 Cr |
| ₹1676 Cr |
| ₹1720 Cr |
| ₹1141 Cr |
| — |
| ₹22 L |
| ₹22 L |
| ₹83,000 |
| ₹83,000 |
| — |
| ₹269 Cr |
| ₹772 Cr |
| ₹1 Cr |
| ₹3 Cr |
| ₹675 Cr |
| ₹1720 Cr |
| ₹44 Cr |
| ₹1720 Cr |
| ₹1 |
| ₹1 |
Cash Flow
Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Closing Cash & Cash Equivalent
| Mar 2025 |
|---|
| ₹4 Cr |
| ₹5 Cr |
| -₹1144 Cr |
| -₹1135 Cr |
| -₹1135 Cr |
| ₹13 L |
| ₹1136 Cr |
| ₹1 Cr |
| ₹1 Cr |
Fundamental Ratios
Consolidated
Standalone
No results found